Prognostic Impact of Circulating Tumor DNA Detection in Portal and Peripheral Blood in Resected Pancreatic Ductal Adenocarcinoma Patients

Overview

Journal Sci Rep

Specialty Science

Date 2024 Nov 8

PMID 39516243

Authors

Charlotte Maulat

Cindy Canivet

Bastien Cabarrou

Anne Pradines

Janick Selves

Anne Casanova

Aurelia Doussine

Naima Hanoun

Emmanuel Cuellar

Paul Boulard

Nicolas Carrere

Louis Buscail

Barbara Bournet

Fabrice Muscari

Pierre Cordelier

Affiliations

Soon will be listed here.

Abstract

In PDAC patients, ctDNA detection's prognostic significance needs validation especially in resected patients. This study investigated ctDNA kinetics in portal and peripheral blood before and after resection, and whether tissue mobilization during surgery influences ctDNA detection. In this single-center prospective cohort, portal and peripheral blood were drawn during pancreaticoduodenectomy before and after tissue mobilization, during 12 postoperative months and were associated with overall survival (OS), recurrence-free survival (RFS) and CA19-9 (secondary endpoints). Tumor mutations were identified using next-generation-sequencing and ctDNA detected by digital droplet PCR. From 2018 to 2022, 34 patients were included. The 2-year RFS and OS were 47.6%(95%CI[29.5; 63.6]) and 65.7%(95%CI[46.5; 79.4]) respectively. Intraoperatively, ctDNA detection in portal or peripheral blood was associated with worse RFS (HR[95%CI]3.26[1.26; 8.45],p = 0.010) and OS (HR[95%CI]5.46[1.65;18.01],p = 0.002). Portal vein sampling did not improve ctDNA detection. CtDNA levels were increased by 2.5-fold (p = 0.031) in peripheral blood after tissue mobilization but not significantly linked to RFS or OS. Detecting ctDNA intraoperatively was correlated with poorer RFS (HR [95% CI] 3.26 [1.26;8.45], p = 0.010) and 0S (HR [95% CI] 5.46 [1.65;18.01], p = 0.002). Portal vein sampling did not improve ctDNA detection. Tissue mobilization increases ctDNA levels. Intraoperative detection of ctDNA is associated with a worse prognosis.

References

Hadano N, Murakami Y, Uemura K, Hashimoto Y, Kondo N, Nakagawa N . Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer. 2016; 115(1):59-65. PMC: 4931379. DOI: 10.1038/bjc.2016.175. View

Poruk K, Gay D, Brown K, Mulvihill J, Boucher K, Scaife C . The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013; 13(3):340-51. PMC: 4419808. DOI: 10.2174/1566524011313030003. View

Yang Z, LaRiviere M, Ko J, Till J, Christensen T, Yee S . A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2020; 26(13):3248-3258. PMC: 7334066. DOI: 10.1158/1078-0432.CCR-19-3313. View

Takii Y, Mizusawa J, Kanemitsu Y, Komori K, Shiozawa M, Ohue M . The Conventional Technique Versus the No-touch Isolation Technique for Primary Tumor Resection in Patients With Colon Cancer (JCOG1006): A Multicenter, Open-label, Randomized, Phase III Trial. Ann Surg. 2022; 275(5):849-855. DOI: 10.1097/SLA.0000000000005241. View

Witkiewicz A, McMillan E, Balaji U, Baek G, Lin W, Mansour J . Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015; 6:6744. PMC: 4403382. DOI: 10.1038/ncomms7744. View

Pappas L, Adalsteinsson V, Parikh A . The emerging promise of liquid biopsies in solid tumors. Nat Cancer. 2022; 3(12):1420-1422. DOI: 10.1038/s43018-022-00498-4. View

Conroy T, Hammel P, Hebbar M, Abdelghani M, Wei A, Raoul J . FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018; 379(25):2395-2406. DOI: 10.1056/NEJMoa1809775. View

Guven D, Sahin T, Yildirim H, Aktepe O, Dizdar O, Yalcin S . A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer. Crit Rev Oncol Hematol. 2021; 168:103528. DOI: 10.1016/j.critrevonc.2021.103528. View

Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D . Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Cancers (Basel). 2021; 13(5). PMC: 7956845. DOI: 10.3390/cancers13050994. View

10.

Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, OReilly E . Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(11):987-1002. DOI: 10.1016/j.annonc.2023.08.009. View

11.

Edland K, Tjensvoll K, Oltedal S, Dalen I, Lapin M, Garresori H . Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging. Mol Oncol. 2023; 17(9):1857-1870. PMC: 10483602. DOI: 10.1002/1878-0261.13472. View

12.

Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M . The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017; 161(3):584-591. DOI: 10.1016/j.surg.2016.11.014. View

13.

Palacin-Aliana I, Garcia-Romero N, Asensi-Puig A, Carrion-Navarro J, Gonzalez-Rumayor V, Ayuso-Sacido A . Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR. Biomedicines. 2021; 9(8). PMC: 8389639. DOI: 10.3390/biomedicines9080906. View

14.

Fleischhacker M, Schmidt B . Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta. 2006; 1775(1):181-232. DOI: 10.1016/j.bbcan.2006.10.001. View

15.

Dekker E, van Dam J, Janssen Q, Besselink M, Desilva A, Doppenberg D . Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. J Clin Oncol. 2024; 42(12):1357-1367. DOI: 10.1200/JCO.23.01311. View

16.

Isaji S, Mizuno S, Windsor J, Bassi C, Fernandez-Del Castillo C, Hackert T . International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2017; 18(1):2-11. DOI: 10.1016/j.pan.2017.11.011. View

17.

Yamaguchi T, Uemura K, Murakami Y, Kondo N, Nakagawa N, Okada K . Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2020; 28(6):3135-3144. DOI: 10.1245/s10434-020-09278-9. View

18.

Shah D, Wells A, Cox M, Dawravoo K, Abad J, DSouza A . Prospective Evaluation of Circulating Tumor DNA using Next Generation Sequencing as a Biomarker during Neoadjuvant Chemotherapy in Localized Pancreatic Cancer. Ann Surg. 2024; . PMC: 11263501. DOI: 10.1097/SLA.0000000000006209. View

19.

Nitschke C, Markmann B, Walter P, Badbaran A, Tolle M, Kropidlowski J . Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma. Clin Chem. 2023; 69(3):295-307. DOI: 10.1093/clinchem/hvac214. View

20.

Qian Z, Rubinson D, Nowak J, Morales-Oyarvide V, Dunne R, Kozak M . Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2017; 4(3):e173420. PMC: 5844844. DOI: 10.1001/jamaoncol.2017.3420. View